Clarity Pharmaceuticals achieves milestones in prostate cancer trial
Clarity Pharmaceuticals (ASX:CU6) has reported significant developments in its SECuRE trial, which is evaluating the efficacy of 67Cu-SAR-bisPSMA for the treatment of prostate cancer. The third participant in cohort 4, a 93-year-old man with over 26 years of prostate cancer history, has completed the Dose Limiting Toxicity (DLT) period after receiving two doses of the […]
Clarity Pharmaceuticals achieves milestones in prostate cancer trial Read More »